No Data
No Data
Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024
Altamira Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
Altamira Shares Decline 5% in Pre-Bell After Pricing of Public Offering
Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering
Express News | Altamira Therapeutics Ltd - License Agreement Extended to Seven Additional Countries in Asia
Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11
No Data
No Data